

Health, 6701 Rockledge Drive, Room 4188, MSC 7808, Bethesda, MD 20892, (301) 435-8008, [younghyd@csr.nih.gov](mailto:younghyd@csr.nih.gov).

*Name of Committee:* Biological Chemistry and Macromolecular Biophysics Integrated Review Group, Biochemistry and Biophysics of Membranes Study Section.

*Date:* June 16-17, 2005.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Gopa Rakhit, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4154, MSC 7806, Bethesda, MD 20892, (301) 435-1721, [rakhitg@csr.nih.gov](mailto:rakhitg@csr.nih.gov).

*Name of Committee:* Health of the Population Integrated Review Group, Nursing Science: Children and Families Study Section.

*Date:* June 16-17, 2005.

*Time:* 9 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Karin F. Helmers, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3166, MSC 7770, Bethesda, MD 20892, (301) 435-1017, [helmersk@csr.nih.gov](mailto:helmersk@csr.nih.gov).

*Name of Committee:* Health of the Population Integrated Review Group, Biostatistical Methods and Research Design Study Section.

*Date:* June 17, 2005.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Jurys Washington Hotel, 1500 New Hampshire Avenue, NW., Washington, DC 20036.

*Contact Person:* Ann Hardy, DRPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3158, MSC 7770, Bethesda, MD 20892, (301) 435-0695, [hardyan@csr.nih.gov](mailto:hardyan@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Software Development and Maintenance.

*Date:* June 17, 2005.

*Time:* 8:30 a.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Marc Rigas, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4194, MSC 7826, Bethesda, MD 20892, (301) 402-1074, [rigasm@csr.nih.gov](mailto:rigasm@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Clinical Hematology.

*Date:* June 17, 2005.

*Time:* 12 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Churchill Hotel, 1914 Connecticut Avenue, NW., Washington, DC 20009.

*Contact Person:* Chhanda L. Ganguly, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118, MSC 7802, Bethesda, MD 20892, (301) 435-1739, [gangulyc@csr.nih.gov](mailto:gangulyc@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: May 4, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-9355 Filed 5-10-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Peptides Useful in the Treatment of Dyslipidemic and Vascular Disorders

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in Provisional Patent Application Serial No. 60/619,392 filed 10/15/2004, titled "Multi Domain Amphipathic Helical Peptides and Methods of Their Use" referenced at DHHS as E-114-2004/0-US-01, to Lipid Sciences, Inc., having a place of business in the state of California. The field of use may be limited to the therapeutic treatment of cardiovascular diseases. The United States of America is the assignee of the patent rights in this invention. The territory may be worldwide. This announcement is the first notice to grant an exclusive license to this technology.

**DATES:** Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before July 11, 2005 will be considered.

**ADDRESSES:** Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Fatima Sayyid, Technology Licensing Specialist, Office of

Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4521; Facsimile: (301) 402-0220; e-mail: [sayyidf@mail.nih.gov](mailto:sayyidf@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** Clearance of excess cholesterol from cells by high density lipoproteins (HDL) is facilitated by the interaction of HDL apolipoprotein with cell surface binding sites or receptors such as ABCA1. ABCA1 is a member of the ATP binding cassette transporter family and is expressed by many cell types. Mutations in the ABCA1 transporter lead to diseases characterized by the accumulation of excess cellular cholesterol, low levels of HDL and an increased risk for cardiovascular disease. Research has demonstrated an inverse correlation between the occurrence of atherosclerotic events and levels of HDL and its most abundant protein constituent, apolipoprotein A-1 (apoA-1). ApoA-1 has been shown to promote lipid efflux from ABCA1 transfected cells. However the nature of the interaction between apoA-1 and ABCA1 is not fully understood. Several other exchangeable type apolipoproteins have been shown to efflux lipid from ABCA1 transfected cells. Although the exchangeable type apolipoproteins do not share a similar primary amino acid sequence, they all contain amphipathic helices, a structural motif known to facilitate the interaction of proteins with lipids. Recently, it has been shown in both animal models and humans that intravenous administration of apoA-1 can reduce the size of atherosclerotic plaques. It has also been observed that synthetic peptide mimics of apoA-1 can promote efflux of excess cholesterol from cells. Therefore, synthetic mimics of apoA-1 can potentially also be used as therapeutic compounds in the prevention and treatment of atherosclerosis.

Currently, there are a wide variety of treatments for dyslipidemia, which include, but are not limited to, pharmacologic regimens (mostly statins), partial ileal bypass surgery, portacaval shunt, liver transplantation, and removal of atherogenic lipoproteins by one of several apheresis procedures.

The subject provisional patent application is directed to the composition of peptides or peptide analogs with multiple amphipathic alpha-helical domains that promote lipid efflux from cells. It further relates to methods for identifying non-cytotoxic peptides that promote lipid efflux from cells that are useful in the treatment and prevention of dyslipidemic and vascular

disorders. Dyslipidemic and vascular disorders amenable to treatment with the isolated multi-domain peptides include, but are not limited to, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, HDL deficiency, apoA-I deficiency, coronary artery disease, atherosclerosis, thrombotic stroke, peripheral vascular disease, restenosis, acute coronary syndrome, and reperfusion myocardial injury.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: May 4, 2005.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-9394 Filed 5-10-05; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Substance Abuse and Mental Health Services Administration (SAMHSA) Drug Testing Advisory Board on June 1-2, 2005.

A portion of the meeting will be open and will include a roll call, general announcements, a Department of Health and Human Services drug testing program update, a Department of Transportation drug testing program update, and a Nuclear Regulatory Commission drug testing program update.

Attendance by the public will be limited to space available. Public comments are welcome. Please

communicate with the individual listed below as contact to make arrangements to comment or to request special accommodations for persons with disabilities.

The Board will also meet to develop the analytical and administrative policies for the final revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Program that were published as proposed revisions in the **Federal Register** on April 13, 2004 (69 FR 19673). The submissions from 285 commenters have been made available to the public on the Web site <http://workplace.samhsa.gov>. This meeting will be conducted in closed session since discussing such public comments in open session and then developing the policies will significantly frustrate the Department's ability to develop the final notice of revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The HHS Office of General Counsel made the determination that such matters are protected by exemption 9(B) of section 552(b) of title 5 U.S.C. and therefore may be closed to the public.

To facilitate entering the building for the open session, public attendees are required to contact Mrs. Giselle Hersh, Division of Workplace Programs, 1 Choke Cherry Road, Room 2-1042, Rockville, MD 20857, 240-276-2605 (telephone) or by e-mail to [Giselle.Hersh@samhsa.hhs.gov](mailto:Giselle.Hersh@samhsa.hhs.gov).

Substantive program information and a roster of Board members may be obtained by accessing the SAMHSA workplace Web site (<http://workplace.samhsa.gov>) or communicating with the contact whose name and telephone number are listed below. The transcript for the open session will be available on the SAMHSA workplace website as soon as possible after the meeting.

*Committee Name:* Substance Abuse and Mental Health Services Administration Drug Testing Advisory Board.

*Meeting Date:* June 1-2, 2005.

*Place:* SAMHSA Building, Sugarloaf Room, 1 Choke Cherry Road, Rockville, Maryland 20850.

*Type:*

*Open:* June 1, 2005; 8:30 a.m.-9:30 a.m.

*Closed:* June 1, 2005; 9:30 a.m.-4:30 p.m.

*Closed:* June 2, 2005; 8:30 a.m.-4:30 p.m.

*Contact:* Donna M. Bush, Ph.D., Executive Secretary, 1 Choke Cherry Road, Room 2-1033, Rockville, Maryland 20857, 240-276-2600 (telephone) and 240-276-2610 (fax), E-mail: [Donna.Bush@samhsa.hhs.gov](mailto:Donna.Bush@samhsa.hhs.gov).

Dated: May 5, 2005.

**Toian Vaughn,**

*Committee Management Officer, SAMHSA.*

[FR Doc. 05-9375 Filed 5-10-05; 8:45 am]

**BILLING CODE 4162-20-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration (SAMHSA)

#### Notice of a Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration (SAMHSA) National Advisory Council in June 2005.

The SAMHSA National Advisory Council will meet in an open session June 27 from 9 a.m. to 12:15 p.m., in San Diego, California. The meeting will include the SAMHSA Administrator's Report, discussions concerning issues on SAMHSA's appropriation and budget, and discussions on current administrative, legislative and program developments. The SAMHSA Council meeting will coincide with the Indian Health Services/SAMHSA Behavioral Health Conference which will be held on June 28 through June 30 in San Diego.

Attendance by the public at the SAMHSA Council meeting will be limited to space available. Public comments are welcome. Please communicate with the individual listed as contact below to make arrangements to comment or to request special accommodations for persons with disabilities.

Substantive program information, a summary of the meeting, and a roster of Council members may be obtained as soon as possible after the meeting, either by accessing the SAMHSA Council Web site, <http://www.samhsa.gov/council/council>, or by communicating with the contact whose name and telephone number are listed below. The transcript for the meeting will also be available on the SAMHSA Council Web site within three weeks after the meeting.

*Committee Name:* Substance Abuse and Mental Health Services Administration National Advisory Council.

*Date/Time:* Monday, June 27, 2005, 9 a.m. to 12:15 p.m. (Open).

*Place:* Hyatt Regency Islandia Hotel and Marina, Islands Ballroom, 1441 Quivira Road, San Diego, California 92109.

*Contact:* Toian Vaughn, Executive Secretary, 1 Choke Cherry Road, Room 8-1089, Rockville, Maryland 20857, Telephone: (240) 276-2307; FAX: (240) 276-2252 and E-mail: [toian.vaughn@samhsa.hhs.gov](mailto:toian.vaughn@samhsa.hhs.gov).